



Published in final edited form as:

Thyroid. 2004 December ; 14(12): 1084–1090. doi:10.1089/thy.2004.14.1084.

Trimester-Specific Changes in Maternal Thyroid Hormone, Thyrotropin, and Thyroglobulin Concentrations During Gestation: Trends and Associations Across Trimesters in Iodine Sufficiency

O.P. Soldin^{1,2}, R.E. Tractenberg³, J.G. Hollowell⁴, J. Jonklaas², N. Janicic², and S.J. Soldin^{2,5,6}

¹Division of Cancer Genetics and Epidemiology, Lombardi Comprehensive Cancer Center, Washington, D.C.

²Division of Endocrinology and Metabolism, Georgetown University School of Medicine, Washington, D.C.

³Department of Biomathematics and Biostatistics, Georgetown University School of Medicine, Washington, D.C.

⁴Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas.

⁵Bioanalytical Core Laboratory, Georgetown Clinical Research Center, Georgetown University Medical Center, Washington, D.C.

⁶Department of Laboratory Medicine, Children's National Medical Center and Departments of Pediatrics and Pathology, The George Washington University School of Medicine, Washington, D.C.

Abstract

Objectives—To describe the interrelationships of thyroid functions based on trimester-specific concentrations in healthy, iodine-sufficient pregnant women across trimesters, and postpartum.

Methods—Circulating total 3,5,3'-triiodothyronine (T₃) and thyroxine (T₄) concentrations were determined simultaneously using liquid chromatography tandem mass-spectrometry (LC/MS/MS). Free thyroxine (FT₄), thyroid-stimulating hormone (TSH), and thyroglobulin (Tg) were measured using immunoassay techniques. Linear mixed effects models and correlations were calculated to determine trends and associations, respectively, in concentrations.

Results and conclusions—Trimester-specific T₃, FT₄, TSH, and Tg concentrations were significantly different between the first and third trimesters (all $p < 0.05$); second and third trimester values were not significantly different for FT₄, TSH, and Tg (all $p > 0.25$) although T₃ was significantly higher in the third, relative to the second trimester. T₄ was not significantly different at any trimester (all $p > 0.80$). With two exceptions, analyte concentrations tended not to be correlated at each trimester and at 1-year postpartum. One exception was that T₃ and T₄ tended to be associated (all $p < 0.05$) at all time points except the third trimester ($\rho = 0.239$, $p > 0.05$). T₄ and FT₄ concentrations tended to correlate positively during pregnancy ($\rho 0.361$ – 0.382 , all $p <$

© Mary Ann Liebert, Inc.

Address reprint requests to: Dr. Offie P. Soldin Division of Endocrinology & Metabolism and Cancer Genetics & Epidemiology Lombardi Cancer Center Georgetown University School of Medicine 3800 Reservoir Road, N.W. L.L., Room S-165-A, Box 571465 Washington D.C. 20057-1465 os35@georgetown.edu.

0.05) but not postpartum ($\rho = 0.179$, $p > 0.05$). Trends suggest that trimester-specific measurements of T_3 , FT_4 , T_g , and possibly TSH are warranted.

Introduction

MATERNAL THYROID DYSFUNCTION can have untoward impact on the progress of pregnancy and on fetal outcomes. As a result of increased concentrations of estrogen, human chorionic gonadotrophin (hCG), and other factors during pregnancy, there are complex changes in the concentrations of 3,5,3'-triiodothyronine (T_3), thyroxine (T_4), and thyrotropin (TSH). As a result of the stimulatory effect of estrogen, thyroid-binding globulin (TBG) synthesis increases, and its plasma clearance decreases (1–3). The concentrations of TBG more than doubles by the 16th to 20th week of gestation (4), and there are moderate decreases in both serum transthyretin and albumin (5). This requires an increase in T_4 and T_3 production in order to maintain adequate pools of free thyroxine (FT_4) and free triiodothyronine (FT_3) for the metabolic needs of the mother and the developmental needs of the fetus. These changes reflect physiologic adaptations to optimize maternal thyroid status for fetal development. After delivery there is a rapid reversal of this process, serum TBG concentrations return to normal within 4–6 weeks and serum T_4 and T_3 return to pregestational serum levels.

The interpretation of the changes in thyroid hormone concentrations during normal pregnancy should be based on an understanding of the normal physiologic changes during pregnancy, the iodine adequacy and ambient goitrogens in different geographical regions, medications and medical considerations (6–10). Goiter frequently accompanies pregnancy in geographic areas with iodine deficiency, but not in iodine-replete areas (11). In areas with adequate iodine, autoimmune thyroid disease is the more common cause of thyroid insufficiency. Our results suggest that there is a need for trimester-specific reference intervals for thyroid-associated analytes, because their monitoring is important for the welfare of the mother as well as the fetus (12). In this study we sought to describe the interrelationships between key thyroid hormones during normal pregnancy and approximately 1-year postpartum in healthy, iodine-sufficient women.

Since the 1990s, tandem mass spectrometry has increasingly become an integral part of clinical laboratory testing and newborn screening programs because of its ability to detect more than 30 disorders in a single blood spot and a single analysis. We recently developed novel methodology using isotope dilution liquid chromatography tandem mass spectrometry (LC/MS/MS) to assay T_3 and T_4 in a single sample. The method has been described and validated (13). This method has advantages over traditional immunoassays which lack specificity, cross-react with other analytes and are also affected by heterophilic, nonspecific antibodies (14,15).

Good accuracy with low susceptibility to interferences of MS/MS measurements is important in the case of thyroid hormones because 99.98% of T_4 and 99.7% of T_3 in serum drawn from healthy adults are normally bound to plasma binding proteins. In addition, FT_4 , TSH, T_g , and antithyroid peroxidase antibody (TPOAb) concentrations were determined on the same samples by current immunoassay techniques. We describe the interrelationships between concentrations of key thyroid hormones, reflecting thyroid function throughout pregnancy and postpartum, in a group of healthy, iodine-sufficient women, to assist clinicians who care for pregnant women and other women of reproductive age in identifying those at risk for thyroid dysfunction, and to diagnose thyroid disorders during pregnancy.

Materials and Methods

Sample preparation

The study was approved by the Georgetown University Medical Center (GUMC) and Karolinska IRB and informed consents were obtained. The samples were obtained from healthy, iodine-sufficient women on normal diets undergoing their first pregnancy. All of the women were of Caucasian inheritance/non-Hispanic, with the mean age of 30 years (25–38 years) attending a pregnancy clinic at the Karolinska Institute, Sweden. The samples were obtained during gestation week 12 (first trimester), gestation week 22 (second trimester), gestation week 32 (third trimester), and approximately 1-year postpartum. Gestational dates were confirmed by ultrasound. All pregnancies were viable, non-multiple pregnancies. This study was part of a larger study assessing steroid hormone levels throughout pregnancy.

Chemicals and reagents

Standards of T₄ and T₃ were purchased from Sigma (St. Louis, MO). A stable deuterium-labeled internal standard, levo-thyroxine-d₂ was synthesized according to procedures described in the literature (16,17) by Dr. T. Class, Chemistry Department, Georgetown University. High-performance liquid chromatography (HPLC) grade methanol was purchased from VWR Scientific (West Chester, PA). All other chemicals were of analytical grade and purchased from Sigma.

Serum samples were stored frozen at –70°C, thawed at room temperature, and all samples were analyzed at the same time. All the women were on normal diets, did not suffer from severe hyperemesis or any known thyroid disease, and had normal thyroid volume. Sweden is an iodine-sufficient country, and although urinary iodine (UI) concentrations were not specifically measured in the women participating in our study, in a different study also conducted in Sweden in 1998 (18) (which did not include the same cohort of women) the mean values (95% confidence interval) for 24-hour urine during gestation week (GW) 11–13 were 1.40 (1.19–1.61) $\mu\text{mol/d}$, GW 24 UI = 1.33 (1.14–1.51) $\mu\text{mol/d}$, GW 32 UI = 1.45 (1.06–1.84) $\mu\text{mol/d}$ and GW 38 UI = 1.14 (0.88–1.39) $\mu\text{mol/d}$.

Total T₄ and total T₃ LC/MS/MS procedures

An API 3000 liquid chromatography tandem mass-spectrometer (SCIEX, Toronto, Canada) equipped with TurboIonSpray and Shimadzu HPLC system was used to perform the analysis. Negative ion multiple reaction-monitoring (MRM) mode was used. LC/MS/MS for T₄ and T₃ was performed as previously described (13). Serum total T₄ values are method-dependent; the typical reference intervals, determined for nonpregnant women using immunoassay, approximate 58–160 nmol/L (4.5–12.6 $\mu\text{g/dL}$). Likewise, serum total T₃ reference intervals, measured by immunoassay for nonpregnant women, approximate 1.2–2.7 nmol/L (80–180 ng/dL).

TSH analysis was performed by immunoassay using the Dade Behring Inc. RxL Dimension Clinical Chemistry Analyzer (Newark, DE). Between-day precision gave coefficients of variation (CVs) less than 10% at all concentrations tested. The manufacturer's reference range for TSH was 0.34–4.82 $\mu\text{IU/mL}$.

FT₄ concentrations were measured by immunoassay using the Dade Behring Inc. RxL Dimension Clinical Chemistry Analyzer (Newark, DE). FT₄ measurements are notorious for being method-dependent (19).

Tg concentrations of serum Tg were measured using the DPC-Immulite Automated Analyzer (Diagnostics Product Corporation, Los Angeles, CA) using DPC reagents and according to the manufacturer's specifications.

TPOAb analysis was conducted on all samples using the DPC-Immulite Automated Analyzer (Diagnostics Product Corporation) using DPC reagents and according to the manufacturer's specifications. TPOAb test was considered positive at levels greater than 35 IU/mL.

Statistical analysis

SPSS version 11.5 (SPSS Inc., Chicago, IL) was used to carry out all of the analyses. Descriptive statistics were calculated for each analyte separately by trimester. Medians, along with means and standard errors are presented in Table 1; TSH values were logarithmically transformed to facilitate the use of normal-theory analytic methods and geometric means (and associated standard errors) were calculated for this analyte. To assess trends in analytes during pregnancy, mixed effects linear regression models were run to determine the effect of trimester on hormone level (with subject a random effect). Nonparametric correlations (Spearman's ρ) were calculated to determine associations between analytes at each time point.

Results

In our attempt to delineate data for serum TSH during the trimesters of pregnancy from pregnant women whom we believe to be without evidence for thyroid disease, we measured TPOAb on all of the women. All of the women in the sample were anti-TPOAb negative during pregnancy. However, three of the women (5.8%) tested TPOAb-positive in the postpartum period. In addition, 2 women had a slightly higher than normal TSH concentration (above 5 mIU/L) during the second trimester. These 5 women (9.6% of sample) were excluded from the analyses. Table 1 presents the descriptive statistics for total T₃, total T₄, FT₄, TSH, and Tg at each trimester and 1-year postpartum for the 47 women whose thyroid function was within normal limits.

T₃ and T₄ concentrations are both higher during pregnancy than in the postpartum period (see also Table 3 described below). T₄ levels remained stable throughout pregnancy. In contrast, T₃ values increased during each successive trimester, with the third trimester mean being approximately 20% higher than the first trimester mean. FT₄ concentrations were lower during pregnancy than in the postpartum period. The mean FT₄ decreased by about 15% from the first trimester to the second and then remained stable during the remainder of pregnancy. TSH concentrations were slightly lower than postpartum values (about 16%) during the first trimester, but remained above the postpartum baseline during the second and third trimester. Tg concentrations during the third trimester were substantially higher (by approximately 25%) than postpartum, first, and second trimester concentrations.

The concentrations of the analytes at each trimester and at 1-year postpartum tended not to correlate with each other, with two exceptions (Table 2). One exception was that T₃ and T₄ (both measured by LC/MS/MS) tended to be associated (Spearman's ρ range 0.407–0.445, all $p < 0.05$) at all time points except the second trimester ($\rho = 0.159$, $p > 0.05$); the second exception was that levels of T₄ and FT₄ tended to correlate positively during pregnancy (ρ range 0.361–0.382, all $p < 0.05$), but not postpartum ($\rho = 0.179$, $p > 0.05$).

Table 3 and Figure 1 show the ratio of mean analyte values for each woman relative to her postpartum baseline, thus showing how each analyte changed over the course of the study. The arithmetic mean for untransformed TSH values is depicted for consistency of scale with

the other analytes. In order to reflect the individualized representation in the mixed effects models and to display all analytes on common axes, we divided the trimester values by the postpartum value of each analyte at each trimester. Thus, a mean ratio value of 1.4 indicates that the average value for the ratio of each woman's measured analyte for that trimester relative to her postpartum value is 1.4.

T₃ levels increased, relative to postpartum levels, at each successive trimester, beginning at an average of 1.20 times the postpartum level in the first trimester to 1.69 by the third trimester. By contrast T₄ beginning at 1.46 in the first trimester did not change during the course of pregnancy. On the other hand, the mean ratio of FT₄ was 0.90 in the first trimester (but dropped to 0.78 in both second and third trimesters. The TSH ratio decreased to 0.8 for the first trimester, rose to 1.11 for the second and third trimester. Tg levels were slightly higher than the postpartum level in the first (1.11) and second (1.07) trimesters and increased to the highest level in the third trimester (1.33).

The changes in some of the analytes during the course of pregnancy are relatively small, compared with the 95% confidence interval (CI). However, the significant progressive increase in T₃ levels throughout pregnancy can be appreciated, as well as a significant early decrease in TSH during the first trimester, increasing during the second trimester. Early decrease in FT₄ with nonoverlapping CIs can also be seen occurring between the first and second trimesters. Differences in these analytes across the trimesters of pregnancy were examined using mixed-effects linear models built with subject as a random effect and trimester as a fixed effect. These models were limited to analyte measurements during pregnancy because of the artifactual effect that inclusion of the postpartum baseline would impart. The linear regression models tested the overall hypothesis that the analyte values were different across trimesters. These were followed by comparisons of measurements of subsequent trimester values (i.e., first to third, second to third). Table 4 presents the results of these models.

T₃, FT₄, and Tg were significantly different across trimesters (all F tests for trimester $p < 0.05$); T₃ levels significantly increased at each successive trimester (both *t* tests comparing first and second to third $p < 0.01$). FT₄ decreased between the first and third trimester ($p < 0.001$), but there was no difference between the second and third trimester values ($p > 0.60$), suggesting that the decrease occurred between the first and second trimesters. TSH increased between the first and third trimester ($p < 0.05$), but not between the second and third trimester ($p > 0.90$), again implying that the increase took place between the first and second trimesters. Tg was significantly associated with trimester ($F(2,3.9) = 9.15$, $p < 0.05$), but changes in Tg levels were not significantly different when trimester-specific concentrations were compared to the third trimester value (both $p > 0.10$). The only analyte that was not significantly different at any trimester was T₄ (both $p > 0.8$).

Discussion

Using the recently developed and standardized LC/MC/MC method to measure total T₄ and total T₃ simultaneously (13), we studied a group of pregnant women, who are believed to be sufficient in iodine and without evidence of thyroid disease. We found changes in total T₄, TSH, FT₄, and that were consistent with the findings of others (7,11,20). In this study T₃ increased through pregnancy and was highest in the third trimester in contrast to other reports of a T₃ plateau at 20 weeks (7). Thus the T₃/T₄ molar ratio actually increased in late pregnancy in these women, although it remained within the normal range (21). We also detected no increase in Tg until the third trimester. Increased Tg has been shown by others in relatively iodine deficient women (22,23).

Tandem mass spectrometry LC/MS/MS has advantages over traditional immunoassays that lack specificity, cross-react with other analytes, and are also affected by heterophilic nonspecific antibodies (14,15). The LC/MS/MS assay for simultaneous measurement of T₃ and T₄ includes stable-isotope internal standards in each sample that allow accuracy and reproducibility. It appears to be largely free of interference or cross-reactivity, a problem that affects immunoassays, as demonstrated in our method-comparison study (24). In comparison to immunoassays that may achieve comparable or better sensitivities and require substantial manual labor and prolonged incubation times, our LC/MS/MS assay is fast, with little hands-on time and no need for sample extraction and derivatization. In our case, because of greater specificity and only measuring the analyte of interest, LC/MS/MS consistently provides somewhat lower results than immunoassays for T₄ (15).

Establishing normal reference intervals for these analytes in women without thyroid dysfunction has important implications for detecting women with thyroid insufficiency in pregnancy who would need to be treated and monitored throughout pregnancy. Specific reference intervals for FT₄, T₄, T₃ in addition to TSH during pregnancy may be particularly important for several reasons. First, it would be important to know what the FT₄ levels are in the first trimester as they are higher than in other trimesters in a euthyroid pregnancy, and this is time when the fetus is wholly dependent on T₄ from the mother. Accurate reference intervals for T₄ and FT₄ would then provide the ability to detect a deficiency at this critical time and provide a subtle indication of maternal hypothyroidism. Such hypothyroxinemia may be masked during the first trimester if that determination relied solely on an elevated TSH because of the stimulatory effect of high hCG levels on the thyroid gland. It is possible that high, sustained estrogen levels during this time are associated with transient lowering of serum TSH (25,26) thus curtailing its rising above the normal nonpregnant range.

Second, maintenance of normal maternal thyroid hormone levels is known to be a determinant of adequate fetal thyroid hormone levels early in pregnancy (20) and adequate mental and psychomotor development in infants (27). Better and easier measurements of T₄ and FT₄ during early pregnancy would contribute to better insights into the more appropriate method of detecting thyroid deficiency at this critical time for the fetus. Mild maternal hypothyroidism (subclinical hypothyroidism) has been implicated as the cause of neuro-psycho-intellectual deficit in offspring (28,29). Accurate reference intervals in early pregnancy would make it possible to better define this condition. In cases of overt hypothyroidism the fetal consequences can be extreme (30). However, it appears that the maternal level and delivery of FT₄ and not T₃ to the fetus is critical for the neuropsychological development of the fetus (31). A deficiency may not be reflected by the degree of TSH elevation (32). It is imperative for normal intervals of thyroid hormones to be established for pregnant women especially if it should be determined necessary that T₄ levels in early pregnancy can be used to screen for fetal and pregnancy risk.

Studies to date have relied on elevated TSH to determine the increment of thyroid hormone needed by hypothyroid patients during pregnancy. Some studies demonstrate that 85% of hypothyroid women needed an increase in LT₄ supplementation during pregnancy (33,34). However, this increased requirement may only be experienced by a subset of hypothyroid patients (35). Once time-specific reference intervals are established, the LC/MS/MS can be used to structure these adjustments individually to support the rate of increase and not just absolute values.

Limitations in this study include the lack of individual urinary iodine measurements of each of the women. Trimester-specific iodine data from a similar population, the knowledge that the population in Sweden is iodine sufficient and the normal thyroid volume were used to support a state of iodine sufficiency. It is possible that the rise of Tg and increased T₃ to T₄

ratio in the third trimester may speak to marginal iodine status becoming manifest at the end of pregnancy, but other thyroid function parameters do not suggest it. We have used the 1-year post pregnancy values to represent prepregnant values.

In conclusion, to our knowledge ours is the first longitudinal study examining T₄ and T₃ levels over time measured by LC/MS/MS in a pregnant population. These results show that, in iodine sufficient women T₃, FT₄, TSH, and Tg tend to change throughout the course of pregnancy, while T₄, after the first trimester, does not. The concentrations of the analytes tended, in general, not to be correlated at each trimester and at 1-year postpartum, although T₄ and FT₄ concentrations tended to correlate positively during pregnancy but not postpartum.

Acknowledgments

This study was supported by National Cancer Institute (NCI) grant 5R01 CA-89950-03 and supported in part by grant M01 RR-13297 from the National Center for Research Resources, National Institutes of Health. The research was conducted at the Georgetown University Medical Center's General Clinical Research Center. The authors are grateful to Dr. L. Hilakivi-Clarke, Georgetown University, and Dr. E. Weiderpass of Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, and International Agency for Research on Cancer, Lyon, France for supplying the serum specimens, and to Dr. N. Soukhova Bioanalytical Core Laboratory, Georgetown Clinical Research Center for technical assistance. Special thanks to Dr. D. Glinoe for reading the manuscript and making helpful suggestions.

References

1. Lum SM, Nicoloff JT, Spencer CA, Kaptein EM. Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. *J Clin Invest*. 1984; 73:570–575. [PubMed: 6699177]
2. Robbins, J. Thyroid Hormone Transport Proteins and Physiology of Hormone Binding. In: Braverman, L.; Utiger, RD., editors. *Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text*. Lippincott-Raven; Philadelphia: 2000. p. 103-120.
3. Schussler GC. The thyroxine-binding proteins. *Thyroid*. 2000; 10:141–149. [PubMed: 10718550]
4. Glinoe D. What happens to the normal thyroid during pregnancy? *Thyroid*. 1999; 9:631–635. [PubMed: 10447005]
5. Bartalena L. Recent achievements in studies on thyroid hormone-binding proteins. *Endocr Rev*. 1990; 11:47–64. [PubMed: 2108013]
6. De Leo V, la Marca A, Lanzetta D, Morgante G. Thyroid function in early pregnancy. I: Thyroid-stimulating hormone response to thyrotropin-releasing hormone. *Gynecol Endocrinol*. 1998; 12:191–196. [PubMed: 9675566]
7. Glinoe D. The regulation of thyroid function in pregnancy: Pathways of endocrine adaptation from physiology to pathology. *Endocr Rev*. 1997; 18:404–433. [PubMed: 9183570]
8. Brent GA. Maternal thyroid function: Interpretation of thyroid function tests in pregnancy. *Clin Obstet Gynecol*. 1997; 40:3–15. [PubMed: 9103946]
9. Kol S, Karnieli E, Kraiem Z, Itskovitz-Eldor J, Lightman A, Ish-Shalom S. Thyroid function in early normal pregnancy: transient suppression of thyroid-stimulating hormone and stimulation of triiodothyronine. *Gynecol Obstet Invest*. 1996; 42:227–229. [PubMed: 8979092]
10. Glinoe D. Maternal thyroid function in pregnancy. *J Endocrinol Invest*. 1993; 16:374–378. [PubMed: 8320430]
11. Berghout A, Ender E, Ross A, Hogerzeil HV, Smits NJ, Wiersinga WM. Thyroid function and thyroid size in normal pregnant women living in an iodine replete area. *Clin Endocrinol*. 1994; 41:375–379.
12. Smallridge RC, Ladenson PW. Hypothyroidism in pregnancy: consequences to neonatal health. *J Clin Endocrinol Metab*. 2001; 86:2349–2353. [PubMed: 11397821]
13. Soukhova N, Soldin OP, Soldin SJ. Isotope dilution tandem mass spectrometric method for T₄/T₃. *Clin Chim Acta*. 2004; 343:185–190. [PubMed: 15115693]

14. Klee GG. Human anti-mouse antibodies. *Arch Pathol Lab Med.* 2000; 124:921–923. [PubMed: 10835540]
15. Soldin OP, Hilakivi-Clarke L, Weiderpass E, Soldin SJ. Thyroxine and triiodothyronine concentrations in pregnancy: Reference intervals defined by isotope dilution tandem mass spectrometry and immunoassays. *Clin Chim Acta.* 2004; 349:181–189. [PubMed: 15469872]
16. Tai SS, Sniegowski LT, Welch MJ. Candidate reference method for total thyroxine in human serum: use of isotope-dilution liquid chromatography-mass spectrometry with electrospray ionization. *Clin Chem.* 2002; 48:637–642. [PubMed: 11901062]
17. Burman KD, Bongiovanni R, Garis RK, Wartofsky L, Boehm TM. Measurement of serum T4 concentration by high performance liquid chromatography. *J Clin Endocrinol Metab.* 1981; 53:909–912. [PubMed: 7287878]
18. Elnagar B, Eltom A, Wide L, Gebre-Medhin M, Karlsson FA. Iodine status, thyroid function and pregnancy: Study of Swedish and Sudanese women. *Eur J Clin Nutr.* 1998; 52:351–355. [PubMed: 9630385]
19. d'Herbomez M, Forzy G, Gasser F, Massart C, Beaudonnet A, Sapin R. Clinical evaluation of nine free thyroxine assays: Persistent problems in particular populations. *Clin Chem Lab Med.* 2003; 41:942–947. [PubMed: 12940522]
20. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. *N Engl J Med.* 1994; 331:1072–1078. [PubMed: 8090169]
21. Weeke J, Dybkjaer L, Granlie K, Eskjaer Jensen S, Kjaerulff E, Laurberg P, Magnusson B. A longitudinal study of serum TSH, and total and free iodothyronines during normal pregnancy. *Acta Endocrinol.* 1982; 101:531–537. [PubMed: 7158229]
22. Rasmussen NG, Hornnes PJ, Hegedus L, Feldt-Rasmussen U. Serum thyroglobulin during the menstrual cycle, during pregnancy, and post partum. *Acta Endocrinol.* 1989; 121:168–173. [PubMed: 2773617]
23. Glinoe D, deNayer P, Bourdoux P, Lemone M, Robyn C, van Steirteghem A, Kinthaert J, Lejeune B. Regulation of maternal thyroid during pregnancy. *J Clin Endocrinol Metab.* 1990; 71:276–287. [PubMed: 2116437]
24. Soldin OP, Tractenberg RE, Soldin SJ. Differences between measurements of T4 and T3 in pregnancy and in non-pregnant women using isotope dilution tandem mass spectrometry and immunoassays: Are there clinical implications? *Clin Chim Acta.* 2004; 347:61–69. [PubMed: 15313142]
25. Franklyn JA, Sheppard MC, Ramsden DB. Serum free thyroxine and free triiodothyronine concentrations in pregnancy. *Br Med J.* 1983; 287:394. [PubMed: 6409320]
26. Burrow GN. Thyroid function and hyperfunction during gestation. *Endocr Rev.* 1993; 14:194–202. [PubMed: 8325252]
27. Pop VJ, Kuijpers JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, Vulsma T, Wiersinga WM, Drexhage HA, Vader HL. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clin Endocrinol.* 1999; 50:149–155.
28. Glinoe D, Delange F. The potential repercussions of maternal, fetal, and neonatal hypothyroxinemia on the progeny. *Thyroid.* 2000; 10:871–887. [PubMed: 11081254]
29. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med.* 1999; 341:549–555. [PubMed: 10451459]
30. Delange F. The role of iodine in brain development. *Proc Nutr Soc.* 2000; 59:75–79. [PubMed: 10828176]
31. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia? *J Clin Endocrinol Metab.* 2000; 85:3975–3987. [PubMed: 11095417]
32. Connolly, KJ.; Pharoah, POD. Iodine deficiency, maternal thyroxine levels in pregnancy and developmental disorders in children. In: Condliffe, PG., editor. *Iodine and the Brain.* Plenum Press; New York: 1989. p. 317-331.

33. Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. *N Engl J Med.* 1990; 323:91–96. [PubMed: 2359428]
34. Kaplan MM. Monitoring thyroxine treatment during pregnancy. *Thyroid.* 1992; 2:147–152. [PubMed: 1525583]
35. Chopra IJ, Baber K. Treatment of primary hypothyroidism during pregnancy: Is there an increase in thyroxine dose requirement in pregnancy? *Metabolism.* 2003; 52:122–128. [PubMed: 12524672]




FIG. 1. Thyroid hormones, thyrotropin (TSH), and thyroglobulin mean ratios by trimester (values relative to 1-year postpartum). Ratios were calculated for each woman relative to her own baseline (postpartum). The means of the ratios are shown.

Table 1

Biochemical Parameters of Thyroid Function (Mean \pm SE) During Gestation and at One-Year Postpartum in Healthy Iodine-Sufficient Women

<i>Analyte</i> *	<i>Trimester</i>			<i>1-Year post partum</i>
	<i>First</i>	<i>Second</i>	<i>Third</i>	
Total T ₃ LC/MS/MS	174.0 \pm 6.0 ng/dL ^{a,b} (2.68 \pm 0.09) nmol/L	182.6 \pm 6.3 (2.81 \pm 0.1)	208.2 \pm 7.18 (3.21 \pm 0.11)	126.0 \pm 4.23 (1.94 \pm 0.06)
Total T ₄ LC/MS/MS	10.0 \pm 0.25 μ g/dL (127.7 \pm 3.6) nmol/L	10.0 \pm 0.26 (127.7 \pm 3.6)	10.1 \pm 0.29 (129.3 \pm 3.6)	7.0 \pm 0.23 (89.2 \pm 2.9)
FT ₄	0.96 \pm 0.03 ng/dL (12.3 \pm 0.4) pmol/L	0.82 \pm 0.02 (10.5 \pm 0.3)	0.82 \pm 0.02 (10.5 \pm 0.2)	1.07 \pm 0.04 (13.6 \pm 0.5)
TSH ^c	0.89 \pm 0.58 mIU/L	1.17 \pm 0.08	1.16 \pm 0.08	1.06 \pm 0.07
Tg	15.48 \pm 1.96 μ g/L	14.92 \pm 2.05	18.55 \pm 2.8	13.95 \pm 1.6

^aValues are given as mean \pm SE in the respective units.

^bFor conversion: T₃ ng/dL \times 0.0154 = nmol/L; T₄ μ g/dL \times 12.8 = nmol/L.

^cTSH values are geometric means and their SEs.

* T₃ triiodothyronine; T₄, thyroxine; LC/MS/MS, liquid chromatography tandem mass spectrometry; FT₄, free thyroxine; TSH, thyrotropin; Tg, thyroglobulin; SE, standard error.

Table 2Correlation Coefficients (Spearman's ρ) for Thyroid Analytes by Trimester

	T_3	T_4	FT_4	Tg	TSH
Trimester 1					
T_3	1				
T_4	0.445 ^a	1			
FT_4	-0.078	0.361 ^a	1		
Tg	0.036	0.256	0.034	1	
TSH	0.257	0.057	-0.05	0.072	1
Trimester 2					
T_3	1				
T_4	0.427 ^a	1			
FT_4	0.076	0.382 ^a	1		
Tg	0.064	0.076	0.092	1	
TSH	0.243	0.084	-0.239	0.105	1
Trimester 3					
T_3	1				
T_4	0.239	1			
FT_4	0.159	0.376 ^b	1		
Tg	0.270	0.202	0.057	1	
TSH	-0.001	-0.061	-0.234	-0.010	1
Postpartum					
T_3	1				
T_4	0.407 ^a	1			
FT_4	0.007	0.179	1		
Tg	0.101	0.185	0.014	1	
TSH	0.204	-0.164	-0.236	0.057	1

^a $p < 0.01$.^b $p < 0.05$. T_3 triiodothyronine; T_4 , thyroxine; FT_4 , free thyroxine; Tg , thyroglobulin; TSH , thyrotropin.

Table 3Ratios of Analyte Value During Pregnancy to Postpartum Level^a

<i>Analyte</i> [*]	<i>First Trimester</i>	<i>Second Trimester</i>	<i>Third Trimester</i>
T ₃ ^b (LC/MS/MS)	1.20 ± (0.06)	1.49 ± (0.06)	1.69 ± (0.06)
T ₄ ^b (LC/MS/MS)	1.46 ± (0.04)	1.46 ± (0.04)	1.46 ± (0.04)
FT ₄ (IA)	0.90 ± (0.03)	0.78 ± (0.01)	0.78 ± (0.02)
TSH ^c (IA)	0.80 ± (0.05)	1.11 ± (0.06)	1.11 ± (0.06)
Tg (IA)	1.11 ± (0.08)	1.07 ± (0.08)	1.33 ± (0.12)

^aValues are dimensionless—the ratios are constant across unit type and mean SEs are given in parenthesis.

^bBoth T₄ and T₃ were measured by LC/MS/MS.

^cTSH values reflect geometric means and their SEs.

^{*}T₃ triiodothyronine; T₄, thyroxine; FT₄, free thyroxine; TSH, thyrotropin; Tg, thyroglobulin; LC/MS/MS, liquid chromatography tandem mass spectrometry; SE, standard error.

Table 4

Results of Mixed Effects Models: Did Analyte Values Differ Over Time?

<i>Analyte/comparison</i> *	<i>Test statistic</i> ^a	<i>p Value</i>
T ₃ ^b (LC/MS/MS)	F(2, 5.1) = 14.02	<i>p</i> < 0.01
First trimester versus third	<i>t</i> (13.6) = -5.2	<i>p</i> < 0.001
Second trimester versus third	<i>t</i> (13.9) = -3.9	<i>p</i> < 0.002
T ₄ ^b (LC/MS/MS)	F(2, 3.9) = 0.33	<i>p</i> > 0.90
First trimester versus third	<i>t</i> (9.8) = -0.08	<i>p</i> > 0.80
Second trimester versus third	<i>t</i> (0.8) = -0.25	<i>p</i> > 0.80
FT ₄ (IA)	F(2, 3.9) = 16.05	<i>p</i> = 0.013
First trimester versus third	<i>t</i> (25.0) = 5.2	<i>p</i> < 0.001
Second trimester versus third	<i>t</i> (7.4) = 0.41	<i>p</i> > 0.60
TSH (by IA) ^c	F(2, 2.6) = 7.74	<i>p</i> = 0.080
First trimester versus third	<i>t</i> (4.48) = -3.3	<i>p</i> = 0.020
Second trimester versus third	<i>t</i> (2.0) = 0.1	<i>p</i> > 0.90
Tg (by IA)	F(2, 3.9) = 9.15	<i>p</i> = 0.034
First trimester versus third	<i>t</i> (5.2) = -1.9	<i>p</i> = 0.119
Second trimester versus third	<i>t</i> (0.7) = -3.1	<i>p</i> = 0.260

^aF statistic reflects overall effect of trimester; *t* statistic reflects comparison of that trimester's mean observation with 3rd trimester's mean observation.

^bT₄ and T₃ were measured by LC/MS/MS.

^cTSH values were log-transformed prior to this analysis.

* T₃ triiodothyronine; T₄, thyroxine; FT₄, free thyroxine; TSH, thyrotropin; Tg, thyroglobulin; LC/MS/MS, liquid chromatography tandem mass spectrometry.